FDA Approves FLUDARABINE PHOSPHATE — Hisun Pharmaceuticals USA, Inc.

Hisun Pharmaceuticals USA, Inc. announced on July 23, 2026, the approval of its Abbreviated New Drug Application for intravenous fludarabine phosphate, aiming to expand accessibility for patients undergoing cancer treatment. The ANDA approval addresses a critical gap in the market by providing a potentially more affordable alternative to existing branded therapies.